Adma Biologics Inc (NASDAQ: ADMA) is 19.13% higher on its value in year-to-date trading and has touched a low of $9.40 and a high of $25.67 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADMA stock was last observed hovering at around $19.84 in the last trading session, with the day’s gains setting it 0.59%.
Currently trading at $20.43, the stock is -0.60% and -1.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.16 million and changing 2.97% at the moment leaves the stock 9.46% off its SMA200. ADMA registered 117.34% gain for a year compared to 6-month gain of -6.37%. The firm has a 50-day simple moving average (SMA 50) of $20.6664 and a 200-day simple moving average (SMA200) of $18.64865.
The stock witnessed a -12.20% loss in the last 1 month and extending the period to 3 months gives it a 29.06%, and is 0.05% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.03% over the week and 3.34% over the month.
Adma Biologics Inc (ADMA) has around 685 employees, a market worth around $4.88B and $459.38M in sales. Current P/E ratio is 24.20 and Fwd P/E is 20.92. Profit margin for the company is 45.01%. Distance from 52-week low is 117.34% and -20.41% from its 52-week high. The company has generated returns on investments over the last 12 months (45.52%).
The EPS is expected to grow by 31.94% this year.
Adma Biologics Inc (ADMA) Top Institutional Holders
477.0 institutions hold shares in Adma Biologics Inc (ADMA), with institutional investors hold 90.75% of the company’s shares. The shares outstanding are 238.53M, and float is at 230.40M with Short Float at 5.79%. Institutions hold 88.40% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 18.64 million shares valued at $208.45 million. The investor’s holdings represent 8.0221% of the ADMA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 14.52 million shares valued at $162.3 million to account for 6.2459 of the shares outstanding. The other top investors are INVESCO LTD. which holds 13.17 million shares representing 5.6668% and valued at over $147.25 million, while NUVEEN ASSET MANAGEMENT, LLC holds 3.8401 of the shares totaling 8.93 million with a market value of $99.78 million.
Adma Biologics Inc (ADMA) Insider Activity
The most recent transaction is an insider sale by Guiheen Lawrence P., the company’s Director. SEC filings show that Guiheen Lawrence P. sold 7,779 shares of the company’s common stock on May 21 ’25 at a price of $20.32 per share for a total of $0.16 million. Following the sale, the insider now owns 0.11 million shares.
Adma Biologics Inc disclosed in a document filed with the SEC on May 22 ’25 that Guiheen Lawrence P. (Director) sold a total of 1,221 shares of the company’s common stock. The trade occurred on May 22 ’25 and was made at $20.12 per share for $24567.0. Following the transaction, the insider now directly holds 0.11 million shares of the ADMA stock.
Still, SEC filings show that on May 21 ’25, Guiheen Lawrence P. (Director) Proposed Sale 9,000 shares at an average price of $20.44 for $0.18 million. The insider now directly holds shares of Adma Biologics Inc (ADMA).
